302 EAST PETTIGREW STREET, DURHAM, NC
Changes in Board, Management or Compensation
Earnings Release
Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Business Update
Precision BioSciences Advances PBGENE-DMD Development, Highlights Pre-clinical Evidence at ASGCT Meeting
Annual Report to Security Holders
Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities